Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

One Fund is Buying This Biotech Stock Although It’s Losing Smart Money’s Support

Page 1 of 2

Alex Denner is still bullish on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and has further increased his stake in the company. As reported in a recent filing with the Securities and Exchange Commission, Denner’s fund, Sarissa Capital Management, now holds 2.35 million shares of Aegerion, up from the 2.03 million shares reported in its latest 13F filing. As a result, Denner and Sarissa have control over approximately 8.23% of Aegerion’s common stock. However, during the second quarter of 2015, the popularity of Aegerion among the hedge funds in our database has slightly decreased.

Alex Denner Sarissa Capital

Alex Denner started Sarissa Capital Management in 2012 following successful spells at Andreas Halvorsen’s Viking Global and Icahn Capital. During his five-year stint as Carl Icahn’s top healthcare investing officer, Denner managed to bring in a profit of roughly $2 billion by picking bio-technology stocks, during a time when most investors shunned them mainly because of regulatory hurdles. After starting Sarissa Capital, he stuck to his guns and is investing almost exclusively in healthcare stocks, overseeing an equity portfolio with an estimated value of $434 million at the end of June. During the second quarter, Denner has made only a few changes to his holdings, most notable being the 26% reduction of his stake in Quest Diagnostics Inc (NYSE:DGX), Sarissa’s third largest position, to 575,000 shares. He also dumped nearly 40% of the fund’s stake in Amgen, Inc. (NASDAQ:AMGN), leaving Sarissa with exactly 200,000 shares, according to its latest 13F filing. The Medicines Company (NASDAQ:MDCO) was still on Denner’s acquisition list, with his fund reporting a 13% increase in its holding to 1.36 million shares by the end of the second quarter.

Alex Denner
Alex Denner
Sarissa Capital Management

We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge funds have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 118% since then and outperformed the S&P 500 Index by around 60 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!